medigraphic.com
Coordinación General de Investigación de la Facultad de Salud Pública y Nutrición y la Dirección General de Sistemas e Informática de la Universidad Autónoma de Nuevo León

2010, Number 4

<< Back

Rev Salud Publica Nutr 2010; 11 (4)

Ácido linoleico conjugado como estrategia para el control de la obesidad

González-Martínez BE, Jiménez-Salas Z, López-Cabanillas LM, Solís-Pérez E

Language: Spanish
References: 64
Page:
PDF size: 116.58 Kb.


ABSTRACT

The obesity and the overweight are defined as an excessive accumulation of fat, that excessive accumulation can harmful to the people´s health. The World Health Organization (WHO) reports 1,600 million of adults with overweight and obesity, where at least 400 millions presents obesity and near 70 millions of them lives in Mexico. To offset this disease there have been designed diverse strategies, some in the food area, producing low calories food or adding some ingredients that promote the energetic expense; one of that kind of added compounds it is the acid linoleic conjugated (CLA), which has effect in diverse aspects of the obesity, like the corporal composition, the increase of fatfree mass and reduction of the fat mass, among others aspects. Nowadays CLA it´s considered by the FDA and the Alimentarius Codex as safe additive, that’s why some countries added CLA in their products, principally at lacteal products.


REFERENCES

  1. Organización Mundial de la Salud, nota descriptiva N°311, 2009, disponible en: http://www.who.int/mediacentre/factsheets/fs311/es/index.html, consultado en: marzo del 2010.

  2. Idem.

  3. Idem.

  4. Hedley A., C. Ogden, C. Johnson, M. Carroll, L. Curtin and K. Flegal. 2009. Prevalence of Overweight and Obesity Among US Children, Adolescents, and Adults, 1999-2002. Journal of American Medical Association. 291, 2847-2850.

  5. Olaiz-Fernández G., J. Rivera-Domarco, T. Shamah-Levy, R. Rojas, S. Villalpando, M. Hernández-Ávila y J. Sepúlveda-Amor. 2006. Encuesta Nacional de Salud y Nutrición 2006. Instituto Nacional de Salud Pública. Cuernavaca, México.

  6. Instituto Mexicano del Seguro Social, comunicado de prensa No 193. Julio de 2009. "Niños y adolescentes obesos y con sobrepeso, con un futuro incierto en salud: IMSS", disponible en: http://www.imss.gob.mx/comunicacion/Comunicados2009/julio.htm, consultado en: marzo del 2010.

  7. Olaiz-Fernández G., et. al. Op. Cit.

  8. López-Alvarenga J. C. y T. González-García. 2001. Enfermedades asociadas a la obesidad. Revista de Endocrinología y Nutrición 9, 77-85.

  9. Matía P., P. Edurne y L. Alfonso. 2007.”Nutrición y Síndrome metabólico”, Revista Española de Salud Pública 81: 489-505 N.° 5, disponible en: http://scielo.isciii.es/pdf/resp/v81n5/colaboracion5.pdf, consultado en: marzo del 2010.

  10. Uribe F. 2010, Instituto de Salud Pública. Opinión de expertos. disponible en: http://www.insp.mx/medios/noticias/index.php?art/id:31, consultado en: marzo del 2010.

  11. Sánchez-Castillo C. y P. E Pichardo-Ontiveros, P. López-R., 2004. Epidemiología de la obesidad. Gaceta Medica Mexicana 140, S3-S20.

  12. Bidlack W. R. 1996. Interrelationship of food, nutrition, diet and health: the National Association of State Universities and Land Grant Colleges White Paper. Journal of the American College of Nutrition 15, 422-433.

  13. Serrano J. y I. Sánchez. 2008. Tendencias en alimentos funcionales contra la obesidad: ingredientes funcionales, alimentos tecnológicamente modificados y dietas completas. Revista Española de Nutrición Comunitaria. Vol.: 14, 243-254.

  14. Caragay A. B. 1992. Cancer-preventive foods and Ingredients. Food Technology 46, 65-68.

  15. Lane H., D. Nagy-Nero and S. Hendrich. 1999. Position of the American Dietetic Association (ADA): Functional foods. J. Am. Diet. Ass. 99(10):1280-81, disponible en: http://www.eatright.org/About/Content.aspx?id=8354 ; consultado en: abril del 2010.

  16. Fereidoon S. 2009. Nutraceuticals and functional foods: Whole versus processed foods. Trends in Food Science & Technology. Vol. 20, 9, 376-387

  17. Ashwell, M. 2001. Functional Foods: a simple scheme for establishing the scientific basis for all claims. Public Health Nutrition 4, 859-863.

  18. Ashwell, M. 2004. Conceptos Sobre Los Alimentos Funcionales. International Life Sciences Institute, ILSI Europe Concise Monograph Series, disponible en http://europe.ilsi.org/file/ILSICMFuncFoodsES5.pdf, Consultado en: marzo del 2010.

  19. Ashwell, M. 2001, Op. cit.

  20. Gómez Ayala A., 2009. CLA un nuevo ingrediente funcional, Revista OFFARM, vol. 28, núm. 2.

  21. Martínez J., 2006. Obesidad y alimentos funcionales, ¿Son eficaces los nuevos ingredientes y productos?, Revista de Medicina de la Universidad de Navarra. Vol. 50, nº 4, 2006, 31-38 31.

  22. Boschmann M. and F. Thieclecke. 2007. The effects of epigallocatechin-3-gallate on thermogenesis and fat oxidation in obese men: A pilot study. Journal of the American College of Nutrition 26, 389S-395S.

  23. Baddini A., 2009 Conjugated linoleic acid (CLA): effect modulation of body composition and lipid profile, Nutr Hosp. 24(4):422.428.

  24. Gómez Ayala, A., Op. cit.

  25. Portillo M. P. y A. Fernández. 2006. Química, metabolismo y fisiología del ácido linoleico conjugado. Corporación Alimentaria Peñasanta, S.A. España. En: NATURLínea con TONALÍN Libro Blanco. Cap. 3 pp. 31-37.

  26. Gómez Ayala, A., Op. cit.

  27. Jung M. Y. and Y. L. Ha. 1999. Conjugated linoleic acid isomers in partially hydrogenated soybean oil obtained during nonselective and selective hydrogenation processes. Journal of Agriculture and Food Chemistry 47, 704-708.

  28. Pariza M. W., Y. Park and M. E. Cook. 2001. The biologically active isomers of conjugated linoleic acid. Progress Lipid Research 40, 283-298.

  29. French, P., C. Stanton, F. Lawless, E. G. O'Riordan, F. J. Monahan, P. J. Caffrey and A. P. Moloney 2000. Fatty acid composition, including conjugated linoleic acid, of intramuscular fat from steers offered grazed grass, grass silage, or concentrate-based diets. Journal of Animal Science 78, 2849-2855.

  30. Nudda, A. M.A. McGuire, G. Battacone and G. Paulina 2005. Seasonal variation in conjugated linoleic acid and vaccenic acid in milk fat of sheep and its transfer to cheese and ricotta J Dairy Sci. 88(4):1311-1319.

  31. Pariza M. W., Y. L. Ha 1990. Conjugated dienoic derivatives of linoleic acid: a new class of anticarcinogens. Medicine Oncology Tumor Pharmacotherapy 7, 169-171.

  32. Forga, Ll., A. Martínez y M. A. Zulet, 2006. Efectos del CLA sobre tumores. Corporación Alimentaria Peñasanta, S.A., España. NATURLínea con TONALÍN Libro Blanco. Cap. 9 pp. 93-103.

  33. Valeille K., J. Férézou, G. Amsler, A. Quignard-Boulangé, M. Parquet, D. Gripois, V. Dorovska-Taran and J. C. Martin. 2005. A cis-9,trans-11-conjugated linoleic acid-rich oil reduces the outcome of atherogenic process in hyperlipidemic hamster. American Journal of Physiology-Heart and Circulatory Physiology 289, 652-659.

  34. Gómez Ayala, A., Op. cit.

  35. Pariza M. W. 2004. Perspective on the safety and effectiveness of conjugated linoleic acid. American Journal of Clinical Nutrition 79, 1132S-1136S.

  36. Gaullier J. M., J. Halse and K. Hoye, 2004. Conjugated linoleic acid supplementation for 12 months reduces body fat mass in healthy overweight humans. American Journal of Clinical Nutrition 79, 1118-1125.

  37. Idem.

  38. Wang Y. and P. J. H. Jones. 2006. Dietary conjugated linoleic acid and body composition. American Journal of Clinical Nutrition 79, 1153S-1158S.

  39. Houseknecht K. L., J. P. Vanden Heuvel, S. Y. Moya-Camarena, C. P. Portocarrero, L. W. Peck, K. P. Níkel and M. A. Belury, 1998. Dietary Conjugated Linoleic Acid Normalizes Impaired Glucosa Tolerante in the Zucker Diabetic Fatt fa/fa Rat. Biochemical and Biophysical Research Communications 244, 678-682.

  40. Nagao K., N. Inoue, Y. M. Wang, B. Shirouchi and T. Yanagita. 2005. Dietary Conjugated Linoleic Acid Alleviates Nonalcoholic Fatty Liver Disease in Zucker (fa/fa) Rats. Journal of Nutrition 135, 9-13.

  41. Risérus U., B. Vessby, J. Ärnlöv and S. Basu. 2004. Effects of cis-9,trans-11 conjugated linoleic acid supplementation on insulin sensitivity, lipid peroxidation, and proinflammatory markers in obese men. American Journal of Clinical Nutrition 80, 279-283.

  42. Moloney F., T. P. Yeow, A. Mullen, J. Nolan and H. M. Roche. 2004. Conjugated linoleic acid supplementation, insulin sensitivity and lipoprotein metabolism in patients with type 2 diabetes mellitus. American Journal of Clinical Nutrition 80, 887-895.

  43. Pariza, M. W., et.al. Op. cit.

  44. Pariza M. W., Y. Park and M. E. Cook. 2000. Mechanisms of Action of Conjugated Linoleic Acid: Evidence and Speculation. Proceedings of the Society for Experimental Biology and Medicine 223, 8-13.

  45. Brown J. M., M. S. Boysen, S. S. Jensen, R. F. Morrison, J. Storkson, R. Lea-Currie, M. Pariza, S. Mandrup and M. K. McIntosh. 2003. Isomer-specific regulation of metabolism and PPARg signaling by CLA in human preadipocytes. Journal of Lipid Research 44, 1287-1300.

  46. Haro A. y R. Artacho. 2006. Ácido linoleico conjugado: interés actual en nutrición humana. Medicina Clínica (Barcelona) Vol.127. 13, 508-515.

  47. Lee J. H., K. H. Cho and M. R. Kim. 2005. Antiatherogenic effects of structured lipid containing conjugated linoleic acid in C57BL/6J mice. Journal of Agriculture and Food Chemistry 53, 7295-7301.

  48. Brown J. M., et.al. Op. cit.

  49. Botelho A. P., L. F. Santos-Zago and A. C. Oliviera 2009. Effect of conjugated linoleic acid supplementation on lipoprotein lipase activity in 3T3-L1 adipocyte culture. Rev. Nutr. vol.22, 5, 767-771.

  50. Arao K., H. Yotsumoto, S. Y. Han, K. Nagao and T. Yanagita. 2004. The 9cis,11trans,13cis Isomer of Conjugated Linoleic Acid Reduces Apolipoprotein B100 Secretion and Triacylglycerol Synthesis in HepG2 Cells. Bioscience, Biotechnology and Biochemistry 68, 2643-2645.

  51. Valeille K., et.al. 2005 Op. cit.

  52. Valeille K., J. Férézou, M. Parquet, G. Amsler, D. Gripois, A. Quignard-Boulangé and J. C. Martin. 2006. The Natural Concentration of the Conjugated Linoleic Acid, cis-9,trans-11 in Milk Fat Has Antiatherogenic Effects in Hyperlipidemic Hamsters. Journal of Nutrition 136, 1305-1310.

  53. Toomey S., H. Roche, D. Fitzgerald and O. Belton. 2003. Regresión of pre-established atherosclerosis in the apoE -/- Mouse by conjugated linoleic acid. Biochemical Society Transactions 31, 1075-1079.

  54. Zabala A., I. Churruca, A. Fernández-Quintela, V. M. Rodríguez, M. T. Macarulla, J. A. Martínez and M. P. Portillo. 2006. trans-10,cis-12 Conjugated linoleic acid inhibits lipoprotein lipase but increases the activity of lipogenic enzymes in adipose tissue from hamsters fed an atherogenic diet. British Journal of Nutrition 95, 1112-1119.

  55. Jiang J., A. Wolf and B. Vessby. 1999. Relation between the intake of milk fat and the occurrence of conjugated linoleic acid in human adipose tissue. American Journal of Clinical Nutrition 70, 21-27.

  56. Ritzenthaler, K. L., M. K. McGuire, R. Falen, T. D. Shultz, N. Dasgupta and M. A. McGuire. 2001. Estimation of conjugated linoleic acid intake by griten dietary assessment methodologies underestimates actual intake evaluated by food duplicate methodology. Journal of Nutrition 131, 1548-1554.

  57. Haro A. y R. Artacho et. al., Op. cit.

  58. Ritzenthaler, K. L., et. al., 2001 Op. cit.

  59. Gómez Ayala A., Op. cit.

  60. Risérus U., et. al., Op. cit.

  61. Gaullier J., et.al. Op. cit.

  62. Fontecha J., y L.M. Rodríguez-Alcalá. 2006. Aspectos Tecnológicos del Tonalín-CLA. Evaluación de la composición lipídica de derivados lácteos suplementados con Tonalín-CLA. Corporación Alimentaria Peñasanta, S.A., España. NATURLínea con TONALÍN Libro Blanco. Cap. 5 pp. 53-62.

  63. Brown J. M., et.al. Op. cit.

  64. Wang Y. and P. J. H. Jones, 2006. Dietary conjugated linoleic acid and body composition. American Journal of Clinical Nutrition 79, 1153S-1158S.




2020     |     www.medigraphic.com